AACR Annual Meeting 2019: New Approaches to Treating Drug-resistant Non-small Cell Lung Cancer
About 80 percent of lung cancers are non-small cell lung cancers (NSCLC), and about 15 to 20 percent of...
Year: 2019: 2019
About 80 percent of lung cancers are non-small cell lung cancers (NSCLC), and about 15 to 20 percent of...
The AACR-Bayer Innovation and Discovery Grants program supports researchers who are seeking to develop new treatment options for cancers...
Although checkpoint inhibitors and other immunotherapies are remarkably effective for patients with some cancers, demonstrating durable antitumor activity and/or...
“Do you want to have fun?” Richard Pazdur, MD, director of the U.S. Food and Drug Administration (FDA) Oncology...
Immune checkpoint inhibitors have become part of the standard of care for more than 14 different cancer types, including...
Persistent infections from pathogens are a major cause of cancer incidence worldwide. An analysis from 2012 indicates that more...
Cancer immunotherapy research has exploded in recent years. This treatment utilizes a patient’s own immune system to recognize and...
A pair of studies presented at the AACR Annual Meeting 2019 demonstrated encouraging clinical outcomes with two different chimeric...
Recent advances in cancer research has led to enormous progress against many cancer types. From 1991 to 2015, we...
The AACR Annual Meeting 2019 features the theme “Integrative Cancer Science • Global Impact • Individualized Patient Care.” That theme provided...